HCV TREATMENT IN AFRICAN AMERICANS VS NON HISPANIC WHIT*

  • Jeffers, Lennox J, (PI)

Project: Research project

Description

The proposed project is a 5-year multicenter open-label trial designed to evaluate the efficacy of 40 kDa Pegylated interferon alfa-2a (Peginterferon alfa-2a) in combination with Ribavirin in the treatment of genotype-1 chronic hepatitis C (HCV, genotype-1) in African American men and women as compared to non-Hispanic whites. The Primary Aim of this proposal is to establish rates of sustained virologic response to a 48-week course of Peginterferon alfa-2a in combination with ribavirin in African Americans as compared to non-Hispanic whites with chronic HCV genotype 1 as assessed at the end of 48-week post-treatment follow-up by HCV RNA (
StatusFinished
Effective start/end date8/21/016/30/06

Funding

  • National Institutes of Health: $156,262.00
  • National Institutes of Health: $365,000.00
  • National Institutes of Health: $375,000.00
  • National Institutes of Health: $219,938.00
  • National Institutes of Health: $175,000.00
  • National Institutes of Health: $116,204.00

Fingerprint

Hispanic Americans
African Americans
Ribavirin
Genotype
Chronic Hepatitis C
Therapeutics
RNA
peginterferon alfa-2a

ASJC

  • Medicine(all)